Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsCazorla, Silvia I
Frank, Fernanda M
Becker, Pablo D
Mirkin, Gerardo A
Corral, Ricardo S
Guzmán, Carlos A
Malchiodi, Emilio L
MetadataShow full item record
AbstractDespite the strong immune responses elicited after natural infection with Trypanosoma cruzi or vaccination against it, parasite survival suggests that these responses are insufficient or inherently inadequate. T. cruzi contains a major cystein proteinase, cruzipain, which has a catalytic N-terminal domain and a C-terminal extension. Immunizations that employed recombinant cruzipain or its N- and C-terminal domains allowed evaluation of the ability of cruzipain to circumvent responses against the catalytic domain. This phenomenon is not a property of the parasite but of cruzipain itself, because recombinant cruzipain triggers a response similar to that of cruzipain during natural or experimental infection. Cruzipain is not the only antigen with a highly immunogenic region of unknown function that somehow protects an essential domain for parasite survival. However, our studies show that this can be reverted by using the N-terminal domain as a tailored immunogen able to redirect host responses to provide enhanced protection.
CitationRedirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. 2010, 202 (1):136-44 J. Infect. Dis.
AffiliationCátedra de Inmunología and Instituto de Estudios de la Inmunidad Humoral (IDEHU), Universidad de BuenosAires, 1113 Buenos Aires, Argentina.
The following license files are associated with this item:
- Cruzipain induces both mucosal and systemic protection against Trypanosoma cruzi in mice.
- Authors: Schnapp AR, Eickhoff CS, Sizemore D, Curtiss R 3rd, Hoft DF
- Issue date: 2002 Sep
- Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
- Authors: Cazorla SI, Frank FM, Becker PD, Corral RS, Guzmán CA, Malchiodi EL
- Issue date: 2008 Apr 7
- Induction of B- and T-cell responses to cruzipain in the murine model of Trypanosoma cruzi infection.
- Authors: Schnapp AR, Eickhoff CS, Scharfstein J, Hoft DF
- Issue date: 2002 Jul
- Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against <i>Trypanosoma cruzi</i> Infection.
- Authors: Antonoglou MB, Sánchez Alberti A, Redolfi DM, Bivona AE, Fernández Lynch MJ, Noli Truant S, Sarratea MB, Iannantuono López LV, Malchiodi EL, Fernández MM
- Issue date: 2020
- Trypanosoma cruzi: the major cysteinyl proteinase (cruzipain) is a relevant immunogen of parasite acidic antigens (FIII).
- Authors: Laderach D, Cerban F, Motran C, Vottero de Cima E, Gea S
- Issue date: 1996 Nov